The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06756932




Registration number
Help: Registration number
NCT06756932
Ethics application status
Help: Ethics application status
Date submitted
Help: Date submitted
24/12/2024
Date registered
Help: Date registered
3/01/2025
Date last updated
Help: Date last updated
14/09/2026

Titles & IDs
Public title
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Scientific title
A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer
Additional trial identifiers [1] 0 0
CTR20250114
Additional trial identifiers [2] 0 0
BGB-21447-102
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Hormone-receptor-positive Breast Cancer 0 0
HER2-negative Breast Cancer 0 0
Metastatic Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment: Drugs - BGB-21447
Treatment: Drugs - Fulvestrant
Treatment: Drugs - BGB-43395

Experimental: Part 1A: BGB-21447 + Fulvestrant - Sequential cohorts of increasing dose levels of BGB-21447 will be evaluated in combination with fulvestrant.

Experimental: Part 1B: BGB-21447 + BGB-43395 + Fulvestrant - Sequential cohorts of increasing dose levels of BGB-21447 will be evaluated in combination with fulvestrant and BGB-43395.

Experimental: BGB-21447 + Fulvestrant Food Effect Substudy - Participants will receive BGB-21447 at the recommended dose with a high-fat meal and under a fasted state in combination with fulvestrant.

Experimental: Part 2: Dose Expansion, BGB-21447 + Fulvestrant - Participants will receive BGB-21447 at the recommended dose(s) for expansion determined in Part 1A in combination with fulvestrant.


Treatment: Drugs: BGB-21447
Administered orally.

Treatment: Drugs: Fulvestrant
Administered via intramuscular injection.

Treatment: Drugs: BGB-43395
Administered orally.

Intervention code [1] 0 0
Treatment: Drugs
Description of the comparator or control
Control group

Outcomes
Primary outcome [1] 0 0
Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [1] 0 0
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 6 months
Primary outcome [2] 0 0
Part 1: Recommended Dose for Expansion (RDFE) of BGB-21447 in combination with fulvestrant and in combination with fulvestrant and BGB-43395
Timepoint [2] 0 0
From first dose of the study drug(s) to 30 days after the last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 6 to 9 months
Primary outcome [3] 0 0
Part 2: Objective Response Rate (ORR)
Timepoint [3] 0 0
Approximately 12 months
Secondary outcome [1] 0 0
Part 1: ORR
Timepoint [1] 0 0
Approximately 12 months
Secondary outcome [2] 0 0
Parts 1 and 2: Duration of Response (DOR)
Timepoint [2] 0 0
Approximately 12 months
Secondary outcome [3] 0 0
Part 1:Time to Response (TTR)
Timepoint [3] 0 0
Approximately 12 months
Secondary outcome [4] 0 0
Part 2: Disease Control Rate (DCR)
Timepoint [4] 0 0
Approximately 12 months
Secondary outcome [5] 0 0
Part 2: Clinical Benefit Rate (CBR)
Timepoint [5] 0 0
Approximately 12 months
Secondary outcome [6] 0 0
Part 2: Progression-Free Survival (PFS)
Timepoint [6] 0 0
Approximately 12 months
Secondary outcome [7] 0 0
Part 2: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [7] 0 0
From the first dose of study drug(s) to 30 days after the last dose; up to approximately 6 months
Secondary outcome [8] 0 0
Maximum observed plasma concentration (Cmax) of BGB-21447 and BGB-43395
Timepoint [8] 0 0
Up to approximately 2 months
Secondary outcome [9] 0 0
Time to reach maximum observed plasma concentration (Tmax) of BGB-21447 and BGB-43395
Timepoint [9] 0 0
Up to approximately 2 months
Secondary outcome [10] 0 0
Area under the concentration-time curve (AUC) of BGB-21447 and BGB-43395
Timepoint [10] 0 0
Up to approximately 2 months
Secondary outcome [11] 0 0
Apparent terminal elimination half-life (t1/2) of BGB-21447 and BGB-43395
Timepoint [11] 0 0
Up to approximately 2 months
Secondary outcome [12] 0 0
Food Effect Substudy: AUC of BGB-21447 under fasted and fed state
Timepoint [12] 0 0
Up to approximately 2 months
Secondary outcome [13] 0 0
Food Effect Substudy: Cmax of BGB-21447 under fasted and fed state
Timepoint [13] 0 0
Up to approximately 2 months

Eligibility
Key inclusion criteria
* Histologically or cytologically confirmed HR+/HER2- metastatic breast cancer. Part 1A and 1B: Participants must have received = 1 prior line(s) of treatment for advanced/metastatic disease, including prior endocrine therapy and CDK4/6 inhibitor in either the adjuvant or advanced/metastatic setting. Part 2: Participants must have received 1-3 prior line(s) of treatment for advanced/metastatic disease, including prior endocrine therapy and CDK4/6 inhibitor in either the adjuvant or advanced/metastatic setting.
* Female participants will be required (either continue ongoing or initiate as soon as feasible) to have ovarian function suppression using gonadotropin-releasing hormone (GnRH) agonists (such as goserelin) or be postmenopausal.
* Male participants may be required to use GnRH agonists when being treated with fulvestrant at the discretion of the investigator.
* Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of = 1.
* Adequate organ function.
* Female participants of childbearing potential and nonsterile male participants with female partners of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study and for 7 days after the last dose of BGB-21447, 6 months after the last dose of BGB-43395, and 2 years after the last dose of fulvestrant.
* Food effect substudy only: Participants who are able and willing to fast overnight (= 10 hours) and consume a high-fat meal.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
* Prior Bcl-2 inhibitor exposure. For triplet combination cohorts only: Prior therapy selectively targeting CDK4.
* Known leptomeningeal disease or uncontrolled, untreated brain metastases.
* Any malignancy = 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, treated papillary thyroid carcinoma, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast).
* For Part 1B: Uncontrolled diabetes.
* History of hepatitis B or active Hepatitis C infection
* China Only: Untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers with HBV DNA > 500 IU/ml (or > 2500 copies/ml) at screening.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Saint Vincents Hospital Sydney - Darlinghurst
Recruitment hospital [2] 0 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [3] 0 0
Sunshine Coast University Private Hospital - Birtinya
Recruitment hospital [4] 0 0
Peter Maccallum Cancer Centre - Melbourne
Recruitment hospital [5] 0 0
Western Health Sunshine Hospital - St Albans
Recruitment hospital [6] 0 0
Linear Clinical Research - Nedlands
Recruitment postcode(s) [1] 0 0
NSW 2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
NSW 2298 - Waratah
Recruitment postcode(s) [3] 0 0
QLD 4575 - Birtinya
Recruitment postcode(s) [4] 0 0
VIC 3000 - Melbourne
Recruitment postcode(s) [5] 0 0
VIC 3021 - St Albans
Recruitment postcode(s) [6] 0 0
WA 6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Iowa
Country [2] 0 0
United States of America
State/province [2] 0 0
Texas
Country [3] 0 0
United States of America
State/province [3] 0 0
Washington
Country [4] 0 0
China
State/province [4] 0 0
Guangdong
Country [5] 0 0
China
State/province [5] 0 0
Henan
Country [6] 0 0
China
State/province [6] 0 0
Shanghai Municipality
Country [7] 0 0
China
State/province [7] 0 0
Tianjin Municipality
Country [8] 0 0
China
State/province [8] 0 0
Zhejiang

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
BeOne Medicines
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
BeOne Medicines
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Study Director
Address 0 0
Country 0 0
Phone 0 0
1.877.828.5568
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
When will data be available (start and end dates)?
See plan description
Available to whom?
See plan description
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://beonemedicines.com/science/clinical-trials/


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.